Sigyn Therapeutics, Inc. announced the appointment of Jerry DeCiccio, CPA, MBA, as chief financial officer. Mr. DeCiccio brings more than 40 years of financial industry experience to the Company, which includes executive roles at publicly traded companies and Ernst &Young. Previously, he was CFO/COO at Intech Electromechanical, CFO/COO at GTC Telecom, CFO at Incomnet Communications, and President at Cerebain Biotech Corp.

Mr. DeCiccio also served in senior financial roles at Parker Hannifin Corp., Waste Management Inc, and Newport Corp. In these roles, he managed finance, accounting, SEC reporting, treasury, human resources, investor relations, and legal departments. He has also been a member of the Board of Directors and Audit Committee for Interplay Entertainment, Inc., and GT Data Corp.

Mr. DeCiccio earned a Bachelor of Science degree in Accounting and Business Administration from Loma Linda University and an MBA in Finance and Systems Technology from the University of Southern California. He is also a Certified Public Accountant in the State of California. Mr. DeCiccio succeeds Jeremy Farrell, who was previously appointed CFO in March of 2022.

In conjunction with the appointment of a new Chief Financial Officer, the Company removed Jeremy Ferrell from his position as CFO of the Company, effective immediately. The circumstances surrounding Mr. Ferrell?s termination are not a result of any disagreements with the Company or any matter relating to the Company?s operations, policies, or practices.